Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Awaiting development
Reference number: GID-TA11670
Expected publication date: TBC
Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2026 when we will write to you about how you can get involved.